Assessment of adverse effects attributed to statin therapy in product labels: a meta-analysis of double-blind randomised controlled trials
The Lancet
•
February 05, 2026
Most labeled statin side effects lack evidence
In blinded large trials, statins did not increase most harms listed on drug labels; small increases were seen mainly in liver blood-test abnormalities. *Individual participant data meta-analysis of double-blind trials; Level 1a (OCEBM).
- Level of evidence
- Level 1a (OCEBM)
- DocG quality score
- 8.5 / 10
Read the full summary free
Patients, intervention, outcomes, results, and clinical applicability in about 300 words — plus new summaries in your inbox 3× per week.
Sign in with Google
